You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 161 No. 20, November 12, 2001 TABLE OF CONTENTS
  Archives
  •  Online Features
  Comments, Opinions, and Brief Case Reports
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (11)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Psychiatry
 •Attention Deficit Hyperactivity Disorder
 •Drug Therapy
 •Adverse Effects
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

DRESS Syndrome Associated With Nevirapine Therapy

Arch Intern Med. 2001;161:2501-2502.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome or hypersensitive syndrome has been associated with the use of aromatic anticonvulsants, sulfonamides, calcium channel blockers, allopurinol, ranitidine, and thalidomide. The clinical manifestations include a diffuse maculopapular rash, fever, multivisceral involvement, eosinophilia, atypical lymphocytosis, and abnormal liver function test results.1

Nevirapine is a potent and selective noncompetitive inhibitor of the reverse transcriptase enzyme of human immunodeficiency virus (HIV) type 1, inhibiting reverse transcriptase by binding to tyrosine components of the enzyme, which are located near the catalytic site.2 It was the first nonnucleoside reverse transcriptase inhibitor approved for clinical use in patients infected with HIV and is used in combination with other antiretroviral agents.3-4

Two cases of DRESS syndrome induced by the use of zalcitabine5 have been reported, and 4 cases were associated with nevirapine therapy.6-7 The following is a report of a new case of DRESS syndrome associated with nevirapine . . . [Full Text of this Article]

Report of a Case


Comment


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Persistent high nevirapine blood level with DRESS syndrome 12 days after interruption of antiretroviral therapy
Breining et al.
BMJ Case Reports 2009;2009:bcr0720080475-bcr0720080475.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2001 American Medical Association. All Rights Reserved.